ad

3 Residential Real Estate Developer, Auto Components Maker and Pharmaceuticals Company Stocks With a Strong Future Roadmap: Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals

Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals: ROE of 11.6% to 14.9% and FY22 to FY26 revenue CAGR of 9.9% to 20.6%. Prices as of 13 Nov 2026.


16 Nov 2026 • 2:22 pm

3 Residential Real Estate Developer, Auto Components Maker and Pharmaceuticals Company Stocks With a Strong Future Roadmap: Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals

Quick Answer

The three homes, mirror parts and medicine stocks to watch are Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals. Their return on equity ranges from 11.6% to 14.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 20.6%. Sandhar Technologies leads on both return on equity at 14.9% and revenue growth at 20.6% a year. Prices are based on the 13 November 2026 close, and this article is educational, not investment advice.

Homes, mirror parts and medicine stocks give investors a way to track businesses that sit close to everyday demand in India. Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals cover a residential real estate developer, an auto components maker and a pharmaceuticals company.

This list covers three homes, mirror parts and medicine stocks with complete current figures: Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals. Every figure comes from the latest reported financials and the 13 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Homes, Mirror Parts and Medicine Stocks?

Homes, mirror parts and medicine stocks are listed companies that build and sell homes and commercial spaces, make mirrors, switches and plastic parts for vehicles, and make and sell medicines for India and global markets. Their earnings depend on home sales, vehicle output and medicine demand.

Homes, Mirror Parts and Medicine Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Lodha Developers 1,220 100,506 24.3 30.7 14.7 0.42
Sandhar Technologies 520.4 3,135 15.1 36.9 14.9 0.86
Lincoln Pharmaceuticals 522.05 1,067 11.1 36.0 11.6 0.01

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing homes, mirror parts and medicine stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Homes, Mirror Parts and Medicine Stocks Have a Strong Roadmap in India?

Homes, mirror parts and medicine stocks have a strong roadmap in India because strong demand for new homes, steady vehicle production and wider access to quality medicines keep widening the market for these companies.

  • Housing. Families buy more new homes.
  • Auto components. Vehicle makers need dependable parts.
  • Pharmaceuticals. Patients need quality medicines.

Why Lodha Developers Features Among These Homes, Mirror Parts and Medicine Stocks

Among the homes, mirror parts and medicine stocks on this list, Lodha Developers, listed as Macrotech Developers, is a leading residential real estate developer in the Mumbai Metropolitan Region, with projects in Pune, Bengaluru and other cities. It also builds industrial and logistics parks.

In the June 2026 quarter, revenue grew 40.6% year on year to Rs 5,097 crore, while net profit rose 103.4% to Rs 1,373 crore. Revenue rose from Rs 9,525 crore in FY22 to Rs 17,120 crore in FY26, a compound annual growth rate of 15.8%.

Net profit grew from Rs 1,208 crore in FY22 to Rs 3,431 crore in FY26, which works out to a compound annual growth rate of 29.8%. The company has a return on equity of 14.7%, a debt to equity ratio of 0.42 and a market capitalisation of Rs 100,506 crore. The stock trades at a P/E of 24.3, below the industry P/E of 30.7.

Roadmap: The company is launching new projects in its core micro-markets while growing its land bank and its industrial parks business. A strong brand supports pre-sales across price points.

What to watch: Track pre-sales bookings, new launches and collections from ongoing projects.

Why Sandhar Technologies Features Among These Homes, Mirror Parts and Medicine Stocks

Among the apartment developer, mirror maker and medicine shares on this list, Sandhar Technologies supplies safety systems, locks, mirrors, wheels, aluminium die castings and sheet metal parts to two-wheeler, commercial vehicle and passenger vehicle makers.

The company has a return on equity of 14.9%, a debt to equity ratio of 0.86 and a market capitalisation of Rs 3,135 crore. The stock trades at a P/E of 15.1, below the industry P/E of 36.9.

Revenue rose from Rs 2,331 crore in FY22 to Rs 4,927 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 55.9 crore in FY22 to Rs 199 crore in FY26, which works out to a compound annual growth rate of 37.3%. In the June 2026 quarter, revenue grew 25.6% year on year to Rs 1,394 crore, while net profit rose 33.1% to Rs 37.3 crore.

Roadmap: The company supplies leading vehicle makers and has been growing its content per vehicle through new product lines. It has also expanded in aluminium die casting and in electronics and mechatronics.

What to watch: Watch new product ramp-ups and growth in the electric two-wheeler segment.

Why Lincoln Pharmaceuticals Features Among These Homes, Mirror Parts and Medicine Stocks

Among the three companies on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.

Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.

In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.

Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.

What to watch: Track branded product growth, export orders and new launches.

Lodha Developers vs Sandhar Technologies vs Lincoln Pharmaceuticals on Key Financials

The table below sets the three homes, mirror parts and medicine stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Lodha Developers 9,525 17,120 15.8% 3,431 20.0%
Sandhar Technologies 2,331 4,927 20.6% 199 4.0%
Lincoln Pharmaceuticals 482 704 9.9% 87.9 12.5%

Sandhar Technologies posts the highest return on equity in this group at 14.9%. Lodha Developers has the largest FY26 revenue at Rs 17,120 crore, and Sandhar Technologies shows the fastest revenue growth with a 20.6% compound annual rate. A useful habit with homes, mirror parts and medicine stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Company Q1 FY26 Revenue (Rs Cr) Q1 FY27 Revenue (Rs Cr) Year-on-Year Growth
Lodha Developers 3,625 5,097 40.6%
Sandhar Technologies 1,110 1,394 25.6%
Lincoln Pharmaceuticals 169 202 19.0%

Key Risks to Check Before Investing in Homes, Mirror Parts and Medicine Stocks

Every theme carries risks that deserve a check before any decision. For these homes, mirror parts and medicine stocks, the main points are: Long-term apartment developer, mirror maker and medicine shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Housing cycles. Real estate and building demand can vary with rates and sentiment.
  • Production cycles. Vehicle output can vary with demand.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter homes, mirror parts and medicine stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Homes, Mirror Parts and Medicine Stocks

Homes, mirror parts and medicine stocks work best when investors track growth, valuation and return on equity side by side. Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals each have a clear plan to grow. Based on the 13 November 2026 close, Lodha Developers trades at Rs 1,220, Sandhar Technologies at Rs 520.4 and Lincoln Pharmaceuticals at Rs 522.05. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these homes, mirror parts and medicine stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track homes, mirror parts and medicine stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are homes, mirror parts and medicine stocks?

Ans. Homes, mirror parts and medicine stocks are listed companies that build and sell homes and commercial spaces, make mirrors, switches and plastic parts for vehicles, and make and sell medicines for India and global markets. Their earnings depend on home sales, vehicle output and medicine demand. This list looks at three of them, Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals, using reported FY22 to FY26 financials and the 13 November 2026 closing prices.

Which homes, mirror parts and medicine stocks are covered in this list?

Ans. This list covers Lodha Developers, Sandhar Technologies and Lincoln Pharmaceuticals. Based on the 13 November 2026 close, Lodha Developers traded at Rs 1,220, Sandhar Technologies at Rs 520.4 and Lincoln Pharmaceuticals at Rs 522.05. Their return on equity ranges from 11.6% to 14.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 9.9% to 20.6%.

Why do homes, mirror parts and medicine stocks have a strong future roadmap in India?

Ans. Homes, mirror parts and medicine stocks have a strong roadmap in India because strong demand for new homes, steady vehicle production and wider access to quality medicines keep widening the market for these companies. The main drivers are as follows. Housing. Families buy more new homes. Auto components. Vehicle makers need dependable parts. Pharmaceuticals. Patients need quality medicines. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Lodha Developers performed financially?

Ans. Revenue rose from Rs 9,525 crore in FY22 to Rs 17,120 crore in FY26, a compound annual growth rate of 15.8%. Net profit grew from Rs 1,208 crore in FY22 to Rs 3,431 crore in FY26, which works out to a compound annual growth rate of 29.8%. In the June 2026 quarter, revenue grew 40.6% year on year to Rs 5,097 crore, while net profit rose 103.4% to Rs 1,373 crore. The company has a return on equity of 14.7%, a debt to equity ratio of 0.42 and a market capitalisation of Rs 100,506 crore. The stock trades at a P/E of 24.3, below the industry P/E of 30.7. Looking ahead, the company is launching new projects in its core micro-markets while growing its land bank and its industrial parks business. A strong brand supports pre-sales across price points.

How has Sandhar Technologies performed financially?

Ans. Revenue rose from Rs 2,331 crore in FY22 to Rs 4,927 crore in FY26, a compound annual growth rate of 20.6%. Net profit grew from Rs 55.9 crore in FY22 to Rs 199 crore in FY26, which works out to a compound annual growth rate of 37.3%. In the June 2026 quarter, revenue grew 25.6% year on year to Rs 1,394 crore, while net profit rose 33.1% to Rs 37.3 crore. The company has a return on equity of 14.9%, a debt to equity ratio of 0.86 and a market capitalisation of Rs 3,135 crore. The stock trades at a P/E of 15.1, below the industry P/E of 36.9. Looking ahead, the company supplies leading vehicle makers and has been growing its content per vehicle through new product lines. It has also expanded in aluminium die casting and in electronics and mechatronics.

How has Lincoln Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.

What risks should investors check before buying homes, mirror parts and medicine stocks?

Ans. Investors should check a few risks before buying homes, mirror parts and medicine stocks. Housing cycles. Real estate and building demand can vary with rates and sentiment. Production cycles. Vehicle output can vary with demand. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of homes, mirror parts and medicine stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 13 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down